Author: admin

Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results: $AVRW

Avenir Wellness Solutions™ ($AVRW)Skin Care Products are Sold at Major Retailers Including Walmart ($WMT), Target ($TGT), CVS Health ($CVS), and Amazon ($AMZN)

– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines. 

– Company Currently Holds 15 Patents. 

– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman. 

– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.

– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.

– Q3 Net Revenue Increased Sequentially from Q2 2023.

– Sales Expected to Increase Significantly During Q4 and Into 2024.

– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.

– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.

– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns.

Avenir Wellness (OTCQB: AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems. The technology, which is based on 15 current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients.  As a vertically integrated platform company, Avenir Wellness (AVRW) looks to partner or license its IP technology with wellness companies worldwide.

Sera Labs, a wholly owned subsidiary of Avenir Wellness (AVRW), creates high-quality products that use science-backed, proprietary formulations. Products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™.  Avenir Wellness (AVRW) Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including opt-in subscriptions, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers including Walmart, CVS, and Target as well as on the Amzon.com platform. 

Avenir Wellness (AVRW) has a current focus on the beauty and wellness markets which are growing at rapid rates. The global wellness sector, despite the pandemic, saw exponential growth in 2021 with a market size of $1.5 trillion, according to McKinsey. There is a strong overall and growing demand for supplements and nutraceuticals, a $587.3 billion market, according to the 2021 Grandview report. The beauty and personal care industry is a $534 billion market now and is set to grow 5.87% year over year according to Terakeet’s 2021 Beauty Industry Report.

Nicole Kidman, After Discovering the Seratopical Revolution On Her Own, is Now the Global Brand Ambassador of Avenir Wellness because She Knows it Works Best.

Avenir Wellness (AVRW) is represented by the famous Nicole Kidmanas a Strategic Partner and Global Brand Ambassador. 

The story of Nicole Kidman’s involvement with Avenir Wellness (AVRW) is detailed on the Company’s website here: https://seralabshealth.com/pages/about and is also described in a recent interview with Avenir Wellness (AVRW) CEO Nancy Duitch on the well followed “New to the Street” Investment program. The interview can be watched at this link: https://www.youtube.com/watch?v=LuBto12YZmc.

To highlight Breast Cancer Awareness Month in October, Avenir Wellness (AVRW) has launched a limited edition Think Pink bundle. In honor of Nicole Kidman, and her ongoing support of the Vanderbilt-Ingram Cancer Center, a portion of proceeds from each bundle sold will be donated to support this worthy cause.

See Nicole Kidman’s inspiring personal video and ordering information here:  https://seralabshealth.com/products/think-pink

Avenir Wellness (AVRW) continues to receive high-profile media attention with exposure for the company’s Seratopical Revolution product line. Avenir Wellness (AVRW) was able to secure coverage in top-tier publications, including CNN Underscored, Page Six, PEOPLE Magazine, and more. These placements garnered over 513M media impressions for the increasingly popular and successful Avenir Wellness (AVRW) Seratopical Revolution brand. 

Some examples of the latest Avenir Wellness (AVRW) media exposure may be seen at the following links: 

SeratopicalRevolution_CNNUnderscored_8.30.23 1.pdf

SeratopicaRevolution_People_8.30.23 1.pdf

Image 9-1-23 at 2.14 PM (1) 1.jpeg

Seratopical_WholeFoodsMag_8.24.23 1.pdf

Positive Q3 Results with New Campaigns Showing Encouraging Results

On November 14th AVRW announced results for the third fiscal quarter ended September 30, 2023.

Key financial highlights for the second quarter included the following:

Avenir Wellness (AVRW) net revenue in the third quarter of 2023 increased sequentially from Q2 2023 to $1.0 million but decreased year-over-year due to the delay in receiving the expected remainder of the asset sale proceeds. Sales are expected to increase during the fourth quarter and into 2024.

Gross margin increased 80 basis points quarter-to-quarter with further expansion expected in the fourth quarter of 2023 with an increase in higher margin direct-to-consumer sales and the launch of our new beauty product releases as well as our new marketing initiatives.

Gross margin for the third quarter decreased by 740 basis points to 72.6% in 2023 compared to the same period in 2022 due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and Walmart which have benefitted in 2023 from our advertising initiatives.

SG&A expenses (excluding non-cash charges) for the third quarter decreased by $721 thousand in 2023 compared to 2022 driven by increased spend on advertising and promotion of $74 thousand, offset in part by lower overhead of $795 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $30 thousand in 2023. Cost reductions and operating leverage are expected to help narrow the operating loss (excluding non-cash charges) in the fourth quarter.

Avenue Wellness (AVRW) CEO Nancy Duitch stated, “Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our second-quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from the second quarter, and we are moving forward with our efforts to further reduce SG&A expenses and maximize operating leverage. Fine-tuning our SEO and successful monthly campaigns like theSkimm continue to deliver as we execute our strategy to build our brands”

Operational Highlights

Avenir Wellness (AVRW) new beauty subscription program has grown sequentially by 50% quarter over quarter.

The DNA Complex hero product continues to perform as its subscription base grows.

Wholesale sales led by Amazon and Walmart continue to grow with all the positive product reviews. Amazon was a particular bright spot with volume growth despite retail price increases to match our e-commerce site which increased margins to 85%.

Impressive Partnership with LA-Based Facial Plastic Surgeon Dr. Michael Persky to Support Latest DNA Complex Product Launch for The Seratopical Brand 

On September 12th, Avenir Wellness (AVRW) announced that renowned plastic surgeon Dr. Michael A. Persky, M.D., F.A.C.S., will help support marketing for the latest launches and advise on new product innovation.

This partnership with Avenir Wellness (AVRW) came about through a long-standing relationship with Nancy Duitch, CEO and Founder of Sera Labs. Dr. Persky will support brand marketing, social, and advertising campaigns for the Avenir Wellness (AVRW) brand’s latest innovation, patent-pending DNA (Deep Nano Actives) Complex, an instant anti-aging skin tightening serum that penetrates deep into the skin. As an advisory board member, Dr. Persky will also advise on formulating the brand’s future plant-based and scientifically grounded products.

For more information on $AVRW visit: www.avenirwellness.com  and  www.Seralabshealth.com

DISCLAIMER:

CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell, or offer to buy any security. CAP/FPS/CA’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell, or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details that were previously disseminated by the companies mentioned in this release or the opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for the dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In light of these uncertainties, the forward-looking events referred to in this release might not occur.

Media Contact
Company Name: Avenir Wellness Solutions, Inc.
Contact Person: Nancy Duitch, CEO
Email: Send Email
Phone: (760) 564-7400
Address:5805 Sepulveda Blvd #801
City: Sherman Oaks
State: California 91411
Country: United States
Website: https://www.avenirwellness.com/

Anime Jacket Unveils a Pantheon of Iconic Anime-Inspired Outerwear for fans across the planet

The collection will enable fans to express their love for their favourite anime characters.

With the winter season fast approaching, a lot of people are looking to upgrade their wardrobe. One store that is helping anime enthusiasts do just that is Anime Jacket. The store offers a comprehensive collection of jackets featuring beloved manga series for fans looking to incorporate their passion into their everyday routine. The jackets feature iconic characters, symbols, and famous anime manga series scenes.

Talking to the press, a spokesperson for the online store said, “We understand the profound connection fans share with manga characters. Our goal is to empower them to wear that connection proudly with trendy fashion. We worked with a team of designers to meticulously craft each jacket so that it captures the essence of the anime, ensuring that fans can carry a piece of their favourite series wherever they go. These jackets aren’t just outerwear; they are a statement of passion and a celebration of the rich narratives and characters that have become integral parts of fans’ lives.”

The extensive collection spans many genres and series, from timeless classics like Naruto, Dragon Ball, and Sailor Moon to modern hits such as My Hero Academia, Attack on Titan, and Demon Slayer.

He went on to add, “Fans love these jackets not just for their stylish designs but also for the sense of belonging and identity they bring. It’s more than just wearing a jacket as it’s a way for like-minded individuals who share the same passion for these incredible stories and characters. When people wear a jacket featuring their favourite anime, it’s a nod to a community that spans the globe. We hope this collection will make us a mecca for enthusiasts seeking a jacket that is a canvas that tells a visual story that resonates with its respective series’s unique themes and aesthetics.”

The store used high-quality materials, ensuring both durability and comfort for fans who want to make these jackets a staple in their wardrobe. As a special offer, the store provides free shipping on orders exceeding $100, encouraging fans to dive into this vibrant world of anime fashion. Fans eager to elevate their style with anime-inspired jackets such as Dragon Ball Jackets, and One Piece Jackets can visit the website today: https://animejacket.com/

Media Contact
Company Name: Anime Jacket
Contact Person: Henry Huang
Email: Send Email
Address:410 N 7th St Apt 5
City: Knoxville
State: IA 50138
Country: United States
Website: https://animejacket.com/

Ghibli Store Unveils Mesmerizing Collection for Anime Enthusiasts Across the Planet

The new collection is bringing the magic of Ghibli’s anime manga series to fans of all age groups.


As one of the most iconic studios in the world today, Studio Ghibli continues to churn out hits after hits every year. To help fans celebrate the creative ventures, Ghibli Store is trying to help. The online store offers a comprehensive assortment that mirrors the studio’s timeless charm.

Talking to the press, a senior manager for the online store said, “Studio Ghibli has undoubtedly woven itself into the fabric of global pop culture. The newly unveiled collection celebrates the captivating narratives from one of the biggest studios in the world that have left a huge mark on the hearts of fans. We want to become a haven for fans where the magic of Studio Ghibli can be experienced and cherished without them having to break the bank. This new collection is a labour of love, a fusion of Ghibli’s artistic brilliance and the passion fans hold for these extraordinary stories. Each item in this collection is a tribute to the enchantment that Studio Ghibli has brought into the lives of millions.”

The collection spans an extensive array of Studio Ghibli’s beloved anime manga series, including classics like My Neighbor Totoro, Kiki’s Delivery, Spirited Away, Howl’s Moving Castle, and Princess Mononoke. The range of items on offer include apparel like Ghibli Plushies, Ghibli Action Figures as well as accessories like phone cases and posters.

He added, “What sets our Ghibli Store apart is not just the range of products but the profound connection we want to have with all fans. As fans ourselves, Ghibli’s anime manga series are more than just stories for us which is why we do our research to produce items that resonate with people of all ages. Owning a piece of this collection is like holding a fragment of the magic that has shaped our imaginations and touched our hearts. We hope that fans appreciate the quality of its merchandise that is durable and will last for a long time.”

To enhance the shopping experience, the Ghibli Store offers express shipping to fans from every corner of the planet. Moreover, as a special promotion, the store is offering a free shipping on orders over $ 40.

Fans eager to revel in the magic of Studio Ghibli can visit the Ghibli Store website today: https://ghiblistudio.store/

Media Contact
Company Name: Ghibli Store
Contact Person: Henry Huang
Email: Send Email
Address:30 Beach Road
City: Auckland
State: AK 1010
Country: New Zealand
Website: https://ghiblistudio.store/

Epilepsy Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Novartis, Pfizer, Sanofi, Takeda Pharma, Abbott, GlaxoSmithKline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Epilepsy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

 

Some of the key takeaways from the Epilepsy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years. 
  • Epilepsy companies working in the treatment market are Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others, are developing therapies for the Epilepsy treatment 
  • Emerging Epilepsy therapies in the different phases of clinical trials are- RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.   
  • In January 2023, Amzell has commenced a randomized, open-label study aimed at assessing the superiority of AMZ002 in treating infantile spasms, a rare form of epilepsy. The primary objective of this study is to compare the efficacy and safety of AMZ002 with Vigabatrin in individuals newly diagnosed with infantile spasms (IS).
  • In March 2022, Lupin has obtained approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Vigabatrin. This anti-epileptic medication is offered in the form of an oral solution USP (500 mg).
  • In March 2022, The medication Ztalmy, developed by Marinus Pharmaceuticals, has been granted approval by the United States Food and Drug Administration (FDA) for the treatment of seizures in individuals diagnosed with CDKL5 deficiency, a genetic type of epilepsy.
  • In October 2021, Amzell BV has obtained a special protocol assessment from the FDA for the Phase III trial of their novel injectable therapy targeting Infantile Epileptic Disease. AMZ002, a sterile injectable hormone, aims to introduce a purified synthetic polypeptide as an alternative to the current FDA-approved treatments for managing epileptic seizures.
  • In March 2021, Xenon Pharmaceuticals has started a clinical trial involving a randomized, double-blind, placebo-controlled, parallel-group, multicenter study. This trial aims to assess the effectiveness, safety, and tolerance of XEN496 when used as additional treatment in about 40 pediatric patients aged between one month and less than six years old diagnosed with KCNQ2-DEE.

 

Epilepsy Overview

A chronic neurological illness called epilepsy is typified by recurrent, frequent seizures that cause atypical behavior. Because the causes, severity, and types of seizures vary, it may be classified as a spectrum disorder. The disorder known as epilepsy is characterized by abnormal or excessive electrical discharges from brain cells that impair brain function.

 

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/epilepsy-pipeline-insight

 

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:

  • RLS103: Receptor Life Sciences
  • CT-010: Cerebral Therapeutics
  • EQU 001: Equilibre Biopharmaceuticals
  • Darigabat: Cerevel Therapeutics
  • Kv7 Program: Elium Therapeutics
  • CG 01: CombiGen
  • OV329: Ovid Therapeutics
  • OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
  • SKL24741: SK Biopharmaceuticals
  • ENX-101: Engrail Therapeutics
  • AMZ002: Amzell
  • XEN496: Xenon Pharmaceuticals Inc.

 

Epilepsy Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Epilepsy Molecule Type

Epilepsy Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Epilepsy Pipeline Therapeutics Assessment

  • Epilepsy Assessment by Product Type
  • Epilepsy By Stage and Product Type
  • Epilepsy Assessment by Route of Administration
  • Epilepsy By Stage and Route of Administration
  • Epilepsy Assessment by Molecule Type
  • Epilepsy by Stage and Molecule Type

 

DelveInsight’s Epilepsy Report covers around 90+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies

 

Some of the key companies in the Epilepsy Therapeutics Market include:

Key companies developing therapies for Epilepsy are – Novartis AG, Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Sunovion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical, GW Pharmaceuticals plc, H. Lundbeck A/S, Alkem Labs., Eisai Co., and others.

 

Epilepsy Pipeline Analysis:

The Epilepsy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
  • Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Epilepsy drugs and therapies

 

Epilepsy Pipeline Market Drivers

  • Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

 

Epilepsy Pipeline Market Barriers

  • However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

 

Scope of Epilepsy Pipeline Drug Insight    

  • Coverage: Global
  • Key Epilepsy Companies: Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others
  • Key Epilepsy Therapies: RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others
  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
  • Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers 

 

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials

 

Table of Contents

1. Epilepsy Report Introduction

2. Epilepsy Executive Summary

3. Epilepsy Overview

4. Epilepsy- Analytical Perspective In-depth Commercial Assessment

5. Epilepsy Pipeline Therapeutics

6. Epilepsy Late Stage Products (Phase II/III)

7. Epilepsy Mid Stage Products (Phase II)

8. Epilepsy Early Stage Products (Phase I)

9. Epilepsy Preclinical Stage Products

10. Epilepsy Therapeutics Assessment

11. Epilepsy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Epilepsy Key Companies

14. Epilepsy Key Products

15. Epilepsy Unmet Needs

16 . Epilepsy Market Drivers and Barriers

17. Epilepsy Future Perspectives and Conclusion

18. Epilepsy Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Novartis, Pfizer, Sanofi, Takeda Pharma, Abbott, GlaxoSmithKline

CRISPR Therapies Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, and Treatment Outlook | eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“CRISPR Therapies Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR Therapies Market.

 

Some of the key takeaways from the CRISPR Therapies Pipeline Report:

  • Companies across the globe are diligently working toward developing novel CRISPR Therapies treatment therapies with a considerable amount of success over the years. 
  • CRISPR Therapies companies working in the treatment market are Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others, are developing therapies for the CRISPR Therapies treatment 
  • Emerging CRISPR Therapies therapies in the different phases of clinical trials are- BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others are expected to have a significant impact on the CRISPR Therapies market in the coming years.   
  • In September 2023, Vertex Pharmaceuticals and CRISPR Therapeutics jointly announced the completion of discussions with the US Food and Drug Administration (FDA) regarding exagamglogene autotemcel (exa-cel). Following these discussions, the FDA granted a rolling review for exa-cel as a potential treatment for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
  • In August 2023, CRISPR Therapeutics has commenced a single-dose, open-label research endeavor focusing on participants diagnosed with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). This study aims to assess the safety and effectiveness of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

 

Get a Free Sample PDF Report to know more about CRISPR Therapies Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight

 

Emerging CRISPR Therapies Drugs Under Different Phases of Clinical Development Include:

  • BEAM-301: Beam Therapeutics
  • TNG260: Tango Therapeutics
  • CTX 130: CRISPR therapeutics
  • CB-010: Caribou Biosciences, Inc.
  • KSQ-4279: KSQ Therapeutics
  • NTLA-2002: Intellia Therapeutics, Inc.
  • LBP-EC01: Locus Biosciences
  • CTX001: CRISPR Therapeutic

 

CRISPR Therapies Route of Administration

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

CRISPR Therapies Molecule Type

CRISPR Therapies Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

CRISPR Therapies Pipeline Therapeutics Assessment

  • CRISPR Therapies Assessment by Product Type
  • CRISPR Therapies By Stage and Product Type
  • CRISPR Therapies Assessment by Route of Administration
  • CRISPR Therapies By Stage and Route of Administration
  • CRISPR Therapies Assessment by Molecule Type
  • CRISPR Therapies by Stage and Molecule Type

 

DelveInsight’s CRISPR Therapies Report covers around 30+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further CRISPR Therapies product details are provided in the report. Download the CRISPR Therapies pipeline report to learn more about the emerging CRISPR Therapies therapies

 

Some of the key companies in the CRISPR Therapies Therapeutics Market include:

Key companies developing therapies for CRISPR Therapies are – eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego, Inari, Ligandal, CRISPR Therapeutics, Mammoth Biosciences, Poseida Therapeutics, Beam Therapeutics, Pairwise, Sherlock Biosciences, and others

 

CRISPR Therapies Pipeline Analysis:

The CRISPR Therapies pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR Therapies with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Therapies Treatment.
  • CRISPR Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • CRISPR Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR Therapies market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about CRISPR Therapies drugs and therapies

 

CRISPR Therapies Pipeline Market Drivers

  • New drugs are discovered employing the novel ways to treat diseases, CRISPR/Cas9 provides extensive opportunities for programmable gene editing are some of the important factors that are fueling the CRISPR Therapies Market.

 

CRISPR Therapies Pipeline Market Barriers

  • However, unwanted immune responses, off-target effects, CRISPR has tangible progress for localized administration and other factors are creating obstacles in the CRISPR Therapies Market growth.

 

Scope of CRISPR Therapies Pipeline Drug Insight    

  • Coverage: Global
  • Key CRISPR Therapies Companies: Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others
  • Key CRISPR Therapies Therapies: BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others
  • CRISPR Therapies Therapeutic Assessment: CRISPR Therapies current marketed and CRISPR Therapies emerging therapies
  • CRISPR Therapies Market Dynamics: CRISPR Therapies market drivers and CRISPR Therapies market barriers 

 

Request for Sample PDF Report for CRISPR Therapies Pipeline Assessment and clinical trials

 

Table of Contents

1. CRISPR Therapies Report Introduction

2. CRISPR Therapies Executive Summary

3. CRISPR Therapies Overview

4. CRISPR Therapies- Analytical Perspective In-depth Commercial Assessment

5. CRISPR Therapies Pipeline Therapeutics

6. CRISPR Therapies Late Stage Products (Phase II/III)

7. CRISPR Therapies Mid Stage Products (Phase II)

8. CRISPR Therapies Early Stage Products (Phase I)

9. CRISPR Therapies Preclinical Stage Products

10. CRISPR Therapies Therapeutics Assessment

11. CRISPR Therapies Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. CRISPR Therapies Key Companies

14. CRISPR Therapies Key Products

15. CRISPR Therapies Unmet Needs

16 . CRISPR Therapies Market Drivers and Barriers

17. CRISPR Therapies Future Perspectives and Conclusion

18. CRISPR Therapies Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CRISPR Therapies Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, and Treatment Outlook | eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences

Palm Pool Care Reinforces Its Commitment To Premier Pool Services in St. George, Utah

Palm Pool Care, a renowned provider of top-tier pool services, today reaffirms its dedication to offering exceptional pool cleaning, maintenance, and equipment repair services in St. George, Utah. This initiative underlines the company’s commitment to ensuring the highest standards of pool care for its local clientele.

Company Overview:

Established in St. George, Palm Pool Care has carved a niche in the pool service industry with its unyielding commitment to quality and customer satisfaction. Known for its comprehensive range of pool services, the company has become synonymous with reliability and expertise in pool care.

Highlight of Services:

Palm Pool Care specializes in several key areas:

–  Acid Washing: Employing a thorough acid wash technique to restore and maintain the brilliance of pool surfaces.
–  Chemical Balancing: Ensuring the health and clarity of pool water through precise chemical balancing, for safe and comfortable swimming.
–  Equipment Maintenance: Conducting comprehensive equipment maintenance to keep filtration and pumping systems running smoothly.
–  Equipment Repair: Offering expert repair services for all pool equipment, from heaters to automated cleaning systems, to extend their lifespan and efficiency.
–  New Equipment Installs: Installing the latest pool equipment to enhance functionality and energy efficiency.
–  Routine Cleaning: Providing regular cleaning services that keep pools spotless and inviting, from skimming to tile scrubbing.

Customer Focus:

“Our mission at Palm Pool Care has always been to provide unmatched service and peace of mind to our customers,” states JJ Melton, Owner & Operator, at Palm Pool Care. “We take pride in our work and are committed to maintaining the health and beauty of the pools in our community here in St. George.”

Quality Assurance:

The team at Palm Pool Care is equipped with the latest tools and knowledge, enabling them to deliver service excellence consistently. Ongoing training ensures they remain at the forefront of industry advancements and best practices.

Community Involvement:

Palm Pool Care is deeply rooted in the St. George community. The company actively engages in local events and initiatives, demonstrating its commitment to the area’s residents and overall wellbeing.

Contact and Information:

For more details on Palm Pool Care’s services or to schedule a consultation, visit https://palmpoolcare.com/ or explore their Google Business Profile.

About Palm Pool Care:

Palm Pool Care is a leading provider of pool cleaning, maintenance, and repair services in St. George, Utah. With a focus on excellence, the company is dedicated to ensuring the best possible care for residential and commercial pools.

Media Contact
Company Name: Palm Pool Care
Contact Person: JJ Melton
Email: Send Email
Phone: 435-527-5090
Country: United States
Website: https://palmpoolcare.com/

“Sweet Economy” Empowers the Construction of the Core Functional Area of Sanya International Tourism Consumption Center

On the evening of December 3, the 27th China ·Sanya Tianya Haijiao International Wedding Festival (hereinafter referred to as “Tianya Haijiao International Wedding Festival”) came to an end. The romantic atmosphere and warm scenes have attracted the newlyweds and tourists from all over the world to gather together and participate in the grand event.

 

Carry out cultural activities to consolidate the cornerstone of Sanya’s wedding industry.

At this wedding festival, Sanya’s wedding tourism products were integrated in an innovative way, driving Sanya’s wedding industry to form a “closed-loop” supply chain, incubating professional wedding institutions with an industrial scale of over RMB 100 million, and leading Sanya’s wedding industry to be stable and prosperous with a good demonstration.

This event attracted more than 50 wedding agencies and wedding travel industry organizations from outside Hainan Province.  Sanya Tourism and Culture Investment Group and five enterprises such as DR Group have signed cooperation contracts respectively to share resources and optimize allocation through cross-regional cooperation, and further promote the upgrading and development of the wedding industry.

This wedding festival has consolidated the cornerstone of Sanya’s wedding industry and enriched the connotation of Sanya’s wedding industry in innovation and integration.

Accumulate the development experience for more than 20 years to boost the flourish of Sanya’s wedding celebration IP

The first Tianya Haijiao International Wedding Festival was held in 1996. Sanya was also in the forefront in building a “sweet economy” brand at that time. 10 years ago, Hainan Province took the lead in promoting wedding+tourism and building a “wedding island” and “honeymoon island” wedding tourism destination in China. Thus, Sanya became the preferred wedding tourism destination in China and created a vibrant wedding tourism IP.

2023 is a crucial year for the construction of Hainan Free Trade Port. Sanya will also seize the opportunity of free trade port construction, dig deep into the brand IP value of Sanya’s special festival activities in wedding tourism, and build a world-class wedding tourism destination.

“Destination wedding” is favored by young people in China.

The young group represented by “Generation Z” has become the main force in China’s consumer market. The population of this group is about 270 million, accounting for 19% of the total population of China, supporting a consumer market of RMB 4 trillion.

They always advocate a sense of ceremony and individuality. At the wedding ceremony, “destination wedding” has been favored by them. This new kind of wedding ceremony breaks the traditional shackles, and the newlyweds can choose their favorite tourism destinations to witness their romance in a dream land composed of lawn, ocean, blue sky and white clouds.

Upgrade the brand of “sweet economy” to realize the double improvement of the wedding industry in scale and quality.

 

In December 2022, it was emphasized at the Central Economic Work Conference that in 2023, efforts would be made to expand domestic demand, and priority should be given to restoring and expanding consumption. According to the Several Measures for Sanya to Build an International Tourism Resort and Promote the Consumption of Cultural Tourism issued by Sanya People’s Government, it is stipulated that the “engine” of consumption should be driven to expand and develop the industry of happiness in Sanya, that is, to build a world-class wedding tourism city and realize the double improvement of the scale and quality of the wedding industry.

In the future, Sanya Tourism and Culture Investment Group will continue to improve the internationalization, specialization, standardization and quality of Sanya’s wedding industry under the guidance of Sanya’s Special Planning for Wedding Industry Development (2023-2025) and the demand of the global wedding consumer market and constantly upgrade the brand of “sweet economy”, build the wedding tourism industry into a new growth point of tourism economy, and empower the construction of the core functional area of Sanya International Tourism Consumption Center. 

Media Contact
Company Name: Goknews
Contact Person: Bella
Email: Send Email
Country: United States
Website: www.goknews.com

Embark on a Mesmerizing Journey that Blends Whimsy, Wisdom, and Wonder

Embark on a Mesmerizing Journey that Blends Whimsy, Wisdom, and Wonder

In an enchanting burst of creativity, children’s book author Miki Taylor jubilantly announces the release of her latest work, Bentley’s Fantabulous Idea. This magical tome is more than a book; it’s a veritable voyage into a world brimming with captivating tales and charming characters.

“Bentley’s Fantabulous Idea is not just a story to read—it’s an experience waiting to be discovered by young, inquisitive minds!” beams Taylor, her voice echoing her signature enthusiasm. This book is a testament to Taylor’s faith in the transformative power of creativity.

Your child will be transported into a kaleidoscopic world filled with awe-inspiring adventures, as they join Bentley, Betty, and the charismatic Mr. Bee in a quest that’s far more than child’s play.

When Betty faces a school assignment dilemma, it’s not just a problem—it’s an invitation to embark on a quest, guided by the boundless creativity of Bentley with the help of “The Crew,” an exuberant ensemble of twenty-one unforgettable characters. Their story unfolds through a tapestry of interactive activities, riddles, and vibrant illustrations that do more than entertain; they make learning an irresistible dance of curiosity and joy.

And while you hear your child chanting the book’s heartwarming mantra, “It’s easy peasy, just pose and grin a little cheesy!”, know this: every giggle is accompanied by a light bulb moment, every chuckle married to a breakthrough in understanding. Each page turned is a step towards embracing life’s wonderful complexities.



Beneath the layers of laughter and luminous colors, “Bentley’s Fantabulous Idea” is a masterclass in life skills. It showcases the untapped potential of teamwork, the art of creative problem-solving, and the resilience found in perseverance. The challenges Betty faces are not just hurdles but stepping-stones, each imparting a lesson more invaluable than the last.

Taylor’s unique narrative style is a heartwarming blend of personal touch and heartfelt emotion. As the readers flip through the pages, they will feel the presence of her late grandmother, symbolized by the red cardinal and African Violet, adding a layer of depth and sentiment to the story.


Don’t just read the book; venture into a vibrant universe of endless possibilities. Let “Bentley’s Fantabulous Idea” be the passport to your child’s limitless imagination, where learning is as delightful and “easy peasy” as posing and grinning a little cheesy!


But the magic doesn’t stop at the book. Miki Taylor has created a treasure trove of resources on her website, www.MikiTaylor.com, where children can find delightful activities, and educators can access a comprehensive guide for integrating Bentley’s Fantabulous Idea into their curriculum.

Join the SuperWowieCoolalisticXBDogalicious party, buy your copy of Bentley’s Fantabulous Idea on Amazon, Bookshop.org or anywhere books are sold.

Follow Miki Taylor on Social Media:


LinkedIn : https://www.linkedin.com/showcase/mikitaylorauthor/

Instagram: https://www.instagram.com/mikitaylorauthor/

Facebook: https://www.facebook.com/Miki-Taylor-Author-117207224629145

Pinterest: https://pin.it/4eMrE87

Twitter: https://twitter.com/MikiTAuthor

TikTok: https://www.tiktok.com/@mikitaylorauthor

YouTube: https://www.youtube.com/channel/UC_tSnN0XaSj23_85RQi83qw

Media Contact
Company Name: Heavy Seas LLC
Contact Person: Olivia Mitchell
Email: Send Email
Phone: +15594217722
City: New York
State: New York
Country: United States
Website: https://www.heavyseas.co/?fbclid=PAAabb0dFdbz_sCgbNSIIzgrbolM8bbtID7ynrhv1Jmpi4LgOhIN-71Ddwt9c

Sickle Cell Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Addmedica, Medunik USA, Bristol Myer

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sickle Cell Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Sickle Cell Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Sickle Cell Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Sickle Cell Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sickle Cell Disease Market.

 

Some of the key takeaways from the Sickle Cell Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Sickle Cell Disease treatment therapies with a considerable amount of success over the years. 
  • Sickle Cell Disease companies working in the treatment market are Hillhurst Biopharmaceuticals, Agios Pharmaceuticals, Novo Nordisk, Afimmune, IHP Therapeutics, Alexion Pharmaceuticals, Prolong Pharmaceuticals, Pfizer, and others, are developing therapies for the Sickle Cell Disease treatment 
  • Emerging Sickle Cell Disease therapies in the different phases of clinical trials are- HBI-002, AG-946, EPI01, Epeleuton, IHP-102, ALXN1820, Sanguinate, Inclacumab, and others are expected to have a significant impact on the Sickle Cell Disease market in the coming years.   
  • In December 2022, Bluebird Bio Inc. declared that the US FDA has removed a partial clinical hold on its gene therapy studies intended for treating sickle cell disease, allowing the studies to proceed.
  • In October 2022, Pfizer Inc. has finalized its acquisition of GBT, a biopharmaceutical company committed to discovering, developing, and delivering transformative treatments for underrepresented patient communities, with a primary focus on sickle cell disease (SCD).
  • In June 2022, GBT, Inc. has revealed that the US FDA awarded inclacumab both orphan drug and rare pediatric disease designations for treating sickle cell disease (SCD).
  • In March 2022, GBT has commenced an open-label extension study aimed at assessing the extended safety of inclacumab in individuals diagnosed with sickle cell disease (SCD) who were part of a previous Inclacumab clinical trial. This study intends to evaluate the safety aspects associated with the prolonged use of inclacumab in participants with SCD who have already finished a prior study involving this treatment.
  • In February 2022, Global Blood Therapeutics Inc. has obtained marketing authorization for Oxbryta to address hemolytic anemia resulting from sickle cell disease (SCD) in both adult and pediatric patients aged 12 years and older. This approval allows for the use of Oxbryta either as a standalone treatment or in combination with hydroxycarbamide.

 

Sickle Cell Disease Overview

Hemoglobin, the protein that delivers oxygen throughout the body, is impacted by a set of hereditary red blood cell abnormalities known as sickle cell disease (SCD). All regions of the body receive oxygen from healthy red blood cells, which are spherical and travel through tiny blood capillaries. A person with sickle cell disease (SCD) has aberrant hemoglobin, which makes red blood cells sticky and rigid, resembling the C-shaped “sickle” used in agriculture.

 

Get a Free Sample PDF Report to know more about Sickle Cell Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight

 

Emerging Sickle Cell Disease Drugs Under Different Phases of Clinical Development Include:

  • HBI-002: Hillhurst Biopharmaceuticals
  • AG-946: Agios Pharmaceuticals
  • EPI01: Novo Nordisk
  • Epeleuton: Afimmune
  • IHP-102: IHP Therapeutics
  • ALXN1820: Alexion Pharmaceuticals
  • Sanguinate: Prolong Pharmaceuticals
  • Inclacumab: Pfizer

 

Sickle Cell Disease Route of Administration

Sickle Cell Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intranasal
  • Intrathecal
  • Intravenous
  • Oral
  • Oral/Intravenous
  • Parenteral
  • Subcutaneous
  • Subcutaneous/Intramuscular
  • Transdermal

 

Sickle Cell Disease Molecule Type

Sickle Cell Disease Products have been categorized under various Molecule types, such as

  • Antisense oligonucleotide
  • Gene therapy
  • Hormones
  • Neuropeptides
  • Oligonucleotides
  • Small Molecule
  • Triglyceride

 

Sickle Cell Disease Pipeline Therapeutics Assessment

  • Sickle Cell Disease Assessment by Product Type
  • Sickle Cell Disease By Stage and Product Type
  • Sickle Cell Disease Assessment by Route of Administration
  • Sickle Cell Disease By Stage and Route of Administration
  • Sickle Cell Disease Assessment by Molecule Type
  • Sickle Cell Disease by Stage and Molecule Type

 

DelveInsight’s Sickle Cell Disease Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Sickle Cell Disease product details are provided in the report. Download the Sickle Cell Disease pipeline report to learn more about the emerging Sickle Cell Disease therapies

 

Some of the key companies in the Sickle Cell Disease Therapeutics Market include:

Key companies developing therapies for Sickle Cell Disease are – Addmedica, Medunik USA, Bristol Myers Squibb Co., Sanofi SA, Novartis AG, Global Blood Therapeutics Inc., Emmaus Medical Inc., Bluebird Biotechnology, Pfizer Inc., Aruvant Sciences Inc., Glycomimetics Inc., Editas Medicine Inc., CRISPR Therapeutic, and others.

 

Sickle Cell Disease Pipeline Analysis:

The Sickle Cell Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sickle Cell Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sickle Cell Disease Treatment.
  • Sickle Cell Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Sickle Cell Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sickle Cell Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Sickle Cell Disease drugs and therapies

 

Sickle Cell Disease Pipeline Market Drivers

  • Increasing prevalence of Sickle Cell Disease, rising initiatives by various governments and private organizations are some of the important factors that are fueling the Sickle Cell Disease Market.

 

Sickle Cell Disease Pipeline Market Barriers

  • However, clinical heterogeneity of the disease, associated complications of the disease and other factors are creating obstacles in the Sickle Cell Disease Market growth.

 

Scope of Sickle Cell Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Sickle Cell Disease Companies: Hillhurst Biopharmaceuticals, Agios Pharmaceuticals, Novo Nordisk, Afimmune, IHP Therapeutics, Alexion Pharmaceuticals, Prolong Pharmaceuticals, Pfizer, and others
  • Key Sickle Cell Disease Therapies: HBI-002, AG-946, EPI01, Epeleuton, IHP-102, ALXN1820, Sanguinate, Inclacumab, and others
  • Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies
  • Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers 

 

Request for Sample PDF Report for Sickle Cell Disease Pipeline Assessment and clinical trials

 

Table of Contents

1. Sickle Cell Disease Report Introduction

2. Sickle Cell Disease Executive Summary

3. Sickle Cell Disease Overview

4. Sickle Cell Disease- Analytical Perspective In-depth Commercial Assessment

5. Sickle Cell Disease Pipeline Therapeutics

6. Sickle Cell Disease Late Stage Products (Phase II/III)

7. Sickle Cell Disease Mid Stage Products (Phase II)

8. Sickle Cell Disease Early Stage Products (Phase I)

9. Sickle Cell Disease Preclinical Stage Products

10. Sickle Cell Disease Therapeutics Assessment

11. Sickle Cell Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sickle Cell Disease Key Companies

14. Sickle Cell Disease Key Products

15. Sickle Cell Disease Unmet Needs

16 . Sickle Cell Disease Market Drivers and Barriers

17. Sickle Cell Disease Future Perspectives and Conclusion

18. Sickle Cell Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Addmedica, Medunik USA, Bristol Myer

Chilipad Bed Cooling System Offers Discounts for the Holiday Season

Chilipad Bed Cooling System Offers Discounts for the Holiday Season
Chilipad delivers the gift of sleep with discounts up to $200.

Chilipad® Bed Cooling Systems, a brand under Sleepme®, a leading name in temperature-regulated sleep solutions, is thrilled to announce its exclusive holiday sale. This sale offers a golden opportunity for customers to experience the best cooling sleep products at reduced prices. For a limited time, customers can save up to $200 on the Chilipad Dock Pro and the Chilipad Cube. So act fast. This exclusive sale ends on January 3, 2024.

As a bonus, the holiday sale includes complimentary free shipping to the 48 contiguous states, making this the opportune moment to invest in unparalleled sleep quality.

For the hot sleeper, the Chilipad Bed Cooling Systems prevent sweaty sleep even in the winter. Its award-winning mattress toppers seamlessly fit over your existing mattress, catering to a range of sizes from Queen to California King, including adjustable beds. All Chilipads come with a control unit that sits under or next to your bed that channels chilled (or heated) water into the Chilipad while you sleep; ensuring a comfortably cool bed. They boast an impressive temperature range from a crisp 55°F to a toasty 115°F.

Chilipad’s top-of-the-line product, Chilipad Dock Pro, includes intuitive technology that allows users to schedule temperature adjustments throughout the night. It offers rapid cooling and warming capabilities and is engineered to swiftly adapt to personal temperature needs.

With its dual-zone control feature, Chilipad caters to the individual temperature preferences of sleep partners. Each side of the bed can be easily customized to different temperatures. This personalized bed cooling system facilitates deeper, more restorative sleep, unlocking the full rejuvenating potential of every night.

The benefits of deep restorative sleep are undeniable. It allows the body and mind to rest and repair, improving overall health and well-being. Chilipad’s precision-engineered technology offers a gateway to deep slumber, enabling users to regulate their sleep environment much more effectively.

Beyond their impressive functionality, the Chilipad systems are user-friendly and simple to install. It only takes minutes to set up over your existing mattress. They are also easy to clean and maintain. With sleep being the cornerstone of wellness, especially during the holiday rush, investing in a Chilipad translates to an investment in restful nights and revitalized mornings.

Don’t miss this limited-time opportunity to give the gift of deep sleep to yourself or someone who is struggling with sleeping hot. For more information about the holiday sale and the Chilipad Bed Cooling Systems, visit sleep.me.

About Sleepme:

Based in Mooresville, North Carolina, Sleepme is a leading provider of cutting-edge sleep solutions that aims to continually push the boundaries of sleep technology. Renowned for the Chilipad Bed Cooling Systems, Sleepme combines advanced temperature regulation and AI integration to improve sleep experiences and consumer health.

Media Contact
Company Name: Sleepme
Contact Person: Alexandria Burcham
Email: Send Email
Country: United States
Website: https://sleep.me/